Comparative Analysis of Efficacy and Safety of Gabapentin Vs Amitriptyline in Patients of Peripheral Neuropathic Pain in Case of Diabetes Mellitus


Affiliations

  • Government Medical College, Patiala, Department of Pharmacology, Punjab, 147001, India
  • Rajindra Hospital, Department of Medicine, Patiala, Punjab, 147001, India
  • Government Medical College, Patiala, Punjab, 147001, India
  • Government Medical College, Patiala, Department of Physiology, Punjab, 147001, India

Abstract

Introduction: Diabetes mellitus frequently leads to development of peripheral neuropathies in almost 30-50% of patients and the most common type of neuropathy associated with this condition is Distal Symmetric Sensorimotor Polyneuropathy (DSPN). Gabapentin and Amitriptyline are two drugs frequently used for the treatment of neuropathic pain associated with type 2 diabetes. Aim of the study: The aim of this study was to compare efficacy and safety of Gabapentin and Amitriptyline in subjects of Type 2 diabetes mellitus with peripheral neuropathic pain. Material and Methods: A prospective, open, randomized, parallel group, comparative study was conducted in 60 patients coming to Department of Medicine, Rajindra Hospital attached to Government Medical College Patiala, to evaluate the efficacy and safety of Gabapentin and Amitriptyline in patients with diabetic peripheral neuropathic pain. The patients fulfilling the inclusion criteria were included in the study after taking written informed consent. The patients were divided into two groups of 30 cases each by simple randomization. Group I patients received Gabapentin 300 mg HS by oral route. Group II patients received Amitriptyline 25 mg HS by oral route. Therapeutic efficacy of both drugs, by using Michigan Neuropathy Screening Instrument (MNSI) was compared at the baseline and at the end of 4 months. Any adverse drug reactions of the respective drug observed in patient were also noted. All the observations thus made were statistically analysed using appropriate tests. Results: Baseline characteristics of the patients in two groups such as age, sex, duration of diabetes were similar (p>0.05). The mean age in group I and group II were 53.40±8.41 years and 57.17±8.55 years, respectively. There was statistically significant reduction in mean MNSI scores in questionnaire part and physical examination part in both the groups. Also, there was statistically significant difference between the two drugs in reducing mean MNSI score. Mean difference between two drugs in reducing MNSI score in history part (0.77±0.16, p<0.01) and physical examination part (0.75±0.19, p<0.01) favoured Gabapentin. No. of adverse drug reactions reported were significantly higher in Amitriptyline group, p value (<0.05) for the difference in ADRs between two drugs was statistically significant. Conclusion: In this study, we concluded that both drugs lead to improvement in signs and symptoms of diabetic neuropathy. Gabapentin was proved to be more efficacious than Amitriptyline. Gabapentin treated patient’s mean MNSI score at the study end point was significantly lower as compared to the Amitriptyline treated patient’s end-point score. Adverse drug reactions reported in our study were mild in both the groups and a significantly higher number of adverse effects were reported in the amitriptyline group. Dizziness and somnolence were two most commonly reported adverse drug reactions.

Keywords

Amitriptyline, Diabetic Peripheral Neuropathic Pain, Efficacy, Gabapentin, Nerve Conduction, Safety

Subject Discipline

Pharmacy

Full Text:

References

Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012; 28(Suppl 1):8– 14. https://doi.org/10.1002/dmrr.2239 PMid:22271716

Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diab care. 2010; 33(10):2285–93. https://doi.org/10.2337/dc10-1303 PMid:20876709 PMCid:PMC2945176

Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo clin proc. 2006; 81(4):s3–11. https://doi.org/10.1016/S0025-6196(11)61474-2

Boulton AJM, Freeman R, Vinik AI, Malik RA, Arezzo JC, Maser RE et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diab Care. 2005; 28(4):956–62. https://doi.org/10.2337/diacare.28.4.956

Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabt med. 2012; 29(7):937–44. https://doi.org/10.1111/j.14645491.2012.03644.x PMid:22417277 PMCid:PMC3641573

Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M. Painful diabetic peripheral neuropathy: Consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011; 27:629–38. https://doi.org/10.1002/dmrr.1225 PMid:21695762

Jensen TS, Backonja MM, Hernandez-Jimenez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res. 2006; 3:108–19. https://doi.org/10.3132/dvdr.2006.013 PMid:17058631

Michigan neuropathy screening instrument (Patient version). University of Michigan; 2000. Available from: www.med.umich.edu/borc/profs/documents/svi/MNSI_ patient.pdf

Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006; 108(5):477–81. https://doi.org/10.1016/j.clineuro.2005.08.003 PMid:16150538

Mete T, Aydin Y, Saka M, Cinar Yavuz H, Bilen S, Yalcin Y, et al. Comparison of efficiencies of michigan neuropathy screening instrument, neurothesiometer, and electromyography for diagnosis of diabetic neuropathy. Int J Endocrinol. 2013; 1–7. https://doi.org/10.1155/2013/821745 PMid:23818897 PMCid:PMC3684087

Chandra M, Garg R, Kaur J, Santram, Kaur N, Pal R. Evaluation of efficacy of Amitriptyline vs. Gabapentin in diabetic peripheral neuropathy. Al Ameen J Med Sci. 2017; 10(3):194–200.

Dallochio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs Amitriptyline in Painful diabetic neuropathy: an open label pilot study. J Pain Symptom Manage. 2000; 20:280–5. https://doi.org/10.1016/S0885-3924(00)00181-0

Serpell MG. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002; (99):557–66. https://doi.org/10.1016/S03043959(02)00255-5

Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A. Chronic pelvic pain treated with gabapentin and amitriptyline: A randomized controlled pilot study. Wien Klin Wochenschr. 2005; 117:1–7. https://doi.org/10.1007/s00508-005-0464-2 PMid:16416358


Refbacks

  • There are currently no refbacks.